Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2010-08-05
2011-12-13
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08076336
ABSTRACT:
The invention relates to novel compounds of formula Iwhere R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
REFERENCES:
patent: 4578464 (1986-03-01), Cregge et al.
patent: 6063847 (2000-05-01), Chackalamannil et al.
patent: 7375236 (2008-05-01), Shimomura et al.
patent: 2004/0152736 (2004-08-01), Chackalamannil et al.
patent: 2004/0242659 (2004-12-01), Tasaka et al.
patent: 2005/0197370 (2005-09-01), Bossenmaier et al.
patent: 2011/0034452 (2011-02-01), Heinelt et al.
patent: 2011/0034456 (2011-02-01), Heinelt et al.
patent: 2011/0034461 (2011-02-01), Heinelt et al.
patent: 2011/0034467 (2011-02-01), Rohrig et al.
patent: 2011/0034468 (2011-02-01), Huang et al.
patent: 2011/0034506 (2011-02-01), Sun et al.
patent: 1391451 (2004-02-01), None
patent: 1391452 (2004-02-01), None
patent: 1394152 (2004-03-01), None
patent: 1813282 (2007-08-01), None
patent: WO03/089428 (2003-10-01), None
patent: WO 2004/078721 (2004-09-01), None
Welch, J. T., et al., The Synthesis and Biological Activity of Pentafluorosulfanyl Analogs of Fluoxetine, Fenfluramine, and Norfenfluramine. Bioorganic & Medicinal Chemistry, vol. 15, (2007), pp. 6659-6666.
Ahn, et al., Binding of a Thrombin Receptor Tethered Ligand Analogue to Human Platelet Thrombin Receptor, Molecular Pharmacology, vol. 51, pp. 350-356, (1997).
Horie, T., et al., Studies on Pyridazine Derivatives. V. 1) Syntheses of 5-Substituted Derivatives of 3-Amino-6-Aikoxypyridazine 2-Oxide, Chem. Pharm. Bull., vol. 11, No. 9, pp. 1157-1167, (1963).
Ziessel, Raymond et al., “Convenient and Multistep Preparation of Oligopyrdines Bearing Multiple Dansyl and Nitroxide Radicals,” Synthesis (2003), No. 14, pp. 2145-2154.
Suzuki, Keisuke et al., “Reductive Pinacol-Type Rearrangement of Chiral a-Mesyloxy Ketones Promoted by Organoaluminum Compounds,” Tetrahedron Letters (1984), vol. 25, No. 34, pp. 3715-3718.
Brass, Skip, “Platelets and Proteases,” Nature (2001), vol. 413, pp. 26-27.
Cristau, Henri-Jean et al., “Les Tribromures de Phosphoniums. Agents de Bromation de Substrats Organiques,” Phosphorus and Sulfur (1985), vol. 25, pp. 357-367.
Cappelli, Andrea et al., “A Non-Peptide NK, Receptor Agonist Showing Subpicomolar Affinity,” Journal of Medicinal Chemistry (2004), vol. 47, pp. 1315-1318.
Choong, Ingrid C. et al., “Identification of Potent and Selective Small-Molecule Inhibitors of Caspase-3 Through the Use of Extended Tethering and Structure-Based Drug Design,” Journal of Medicinal Chemistry (2002), vol. 45, pp. 5005-5022.
Hollenberg, Morey D. et al., “International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors,” Pharmacological Reviews (2002), vol. 54, No. 2, pp. 203-217.
“Abstracts selected for ESC 2007 Sep. 1-5, 2007, Vienna-Austria,” European Heart Journal (2007), vol. 28 (Abstract Supplement), iii-vi.
Saito, Naoki et al., “A Facile Synthesis of 1,2,3,4-Tetrahydroisoquinolines through Cyclization of O,N-Acetals. II. Syntheses of Isoquinolinequinone Antibiotics,” Chemical and Pharmaceutical Bulletin (1989), vol. 37, pp. 1493-1499.
Chackalamannil, Samuel et al., “Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents,” Expert Opinion on Therapeutic Patents (2006), vol. 16, pp. 493-505.
Lebsack, Alec D. et al., “Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the a2d-1 subunit of voltage gated calcium channel,” Bioorganic and Medicinal Chemistry Letters (2004), vol. 14, pp. 2463-2467.
Cui, Jingrong Jean et al., “Non-Covalent Thrombin Inhibitors Featuring P3-Heterocycles with P1-Bicyclic Arginine Surrogates,” Bioorganic and Medicinal Chemistry Letters (2002) vol. 12, pp. 2925-2930.
International Preliminary Report on Patentability dated Sep. 7, 2010.
European Search Report dated Jul. 2, 2008 issued in EP 08 29 0112.
European Heart Journal, vol. 28, Suppl. 1 (2007), pp. 3-250.
Heinelt Uwe
Herrmann Matthias
Scheiper Bodo
Schoenafinger Karl
Steinhagen Henning
Bender Kelly L.
Jaisle Cecilia M
Lin Jiang
Moore Susanna
Ort Ronald G.
LandOfFree
Triazolopyridazines as PAR1 inhibitors, production thereof,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyridazines as PAR1 inhibitors, production thereof,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyridazines as PAR1 inhibitors, production thereof,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268377